Table 1. Anti-CD2 48 MoAb Inhibit... | American Society of Hematology

Table 1.

Anti-CD2 + 48 MoAb Inhibit Long-Term Alloengraftment in Irradiated B6 Recipients of T-Cell–Depleted BALB/c or DBA/1 Donor BM

Group	No. H2 Typed	Day Post-BMT	% Donor	% Host
A. BALB/c Donors
Irrelevant IgG	28	40-57	60 ± 7	40 ± 7
αCD2 + 48 MoAb	29	40-57	20 ± 6^*	80 ± 6^*
Irrelevant IgG	20	110-145	74 ± 7	26 ± 7
αCD2 + 48 MoAb	23	110-145	38 ± 9^*	62 ± 9^*
B. DBA/1 Donors
Irrelevant IgG	9	40	60 ± 12	39 ± 12
αCD2 + 48 MoAb	11	40	13 ± 8^*	87 ± 8^*
αCD2 MoAb	13	40	66 ± 7	34 ± 7
αCD48 MoAb	2	40	0 ± 0^†	100 ± 0^†
Irrelevant MoAb	8	104	80 ± 12	20 ± 12
αCD2 + 48 MoAb	8	104	22 ± 14^*	87 ± 14^*
αCD2 MoAb	8	104	81 ± 12	19 ± 12
αCD48 MoAb	1	104	0	100

Group	No. H2 Typed	Day Post-BMT	% Donor	% Host
A. BALB/c Donors
Irrelevant IgG	28	40-57	60 ± 7	40 ± 7
αCD2 + 48 MoAb	29	40-57	20 ± 6^*	80 ± 6^*
Irrelevant IgG	20	110-145	74 ± 7	26 ± 7
αCD2 + 48 MoAb	23	110-145	38 ± 9^*	62 ± 9^*
B. DBA/1 Donors
Irrelevant IgG	9	40	60 ± 12	39 ± 12
αCD2 + 48 MoAb	11	40	13 ± 8^*	87 ± 8^*
αCD2 MoAb	13	40	66 ± 7	34 ± 7
αCD48 MoAb	2	40	0 ± 0^†	100 ± 0^†
Irrelevant MoAb	8	104	80 ± 12	20 ± 12
αCD2 + 48 MoAb	8	104	22 ± 14^*	87 ± 14^*
αCD2 MoAb	8	104	81 ± 12	19 ± 12
αCD48 MoAb	1	104	0	100

B6 recipients were administered 6.0 or 6.5 Gy TBI on day −1 followed by 10⁷ T-cell–depleted BM from the indicated donor strain on day 0. Mice received αCD2 + 48 MoAb (300 μg/dose each) or irrelevant IgG IP on days −1 and +2 and then twice weekly through day 14 post-BMT. Data in A are pooled from three experiments consisting of 40 mice per group. Data in B are derived from an experiment in which 15 mice per group were transplanted. All surviving mice were H2 phenotyped at the indicated time periods post-BMT. The % donor and % host cells are the mean ± 1 SEM.

P ≤ .01 as compared with irrelevant IgG control group.

†

P ≤ .05 as compared with irrelevant IgG control group.

View Large

This Feature Is Available To Subscribers Only